Strategies for Using Anticoagulation Therapy in Patients With Cancer
Although approximately 20% to 30% of patients with cancer will develop venous thromboembolism (VTE), clinicians continue to debate strategies for pharmacologic treatment and prevention.1 At the 2018 Debates...
AACR Releases Annual Cancer Progress Report
The American Association for Cancer Research (AACR) has released its annual Cancer Progress Report,1 highlighting how federally funded research discoveries are fueling the development of new and...
Osimertinib in First-Line Treatment of EGFR-Mutant Metastatic NSCLC
In April 2018, osimertinib (Tagrisso) was approved for the first-line treatment of metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon...
Rituximab/Lenalidomide vs Rituximab/Chemotherapy in Advanced Untreated Follicular Lymphoma
In the phase III RELEVANCE trial reported in The New England Journal of Medicine by Franck Morschhauser, MD, PhD, of The University of Lille, Centre Hospitalier Universitaire Lille, France, and colleagues, no...
Adherence to Oral Anticancer Treatment: Priorities in Lymphoma and CLL
Advances in cancer treatment have been nothing short of breathtaking in recent years. Among the most important has been the advent of effective oral therapies, marking a significant...
Jonathan Friedberg: Relevance of the RELEVANCE Trial
Chandrakanth Are: Wear That White Coat—With Pride
Christiane Querfeld: Targeting CCR4 in Cutaneous T-Cell Lymphoma
Leisha Emens: PARP Inhibitors for Advanced Breast Cancer With Germline BRCA Mutation
Stephanie Graff: An Invitation to Be Quiet No Longer
More Top Stories
A Pathologic Fascination With Humanity
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Genomic Classification of Myeloproliferative Neoplasms and Integration in Predictive Models
In a study reported in The New England Journal of Medicine, Grinfeld et al identified distinct genomic subgroups among patients with myeloproliferative neoplasms that, when combined with clinical variables, offered the potential for individualized predictions of clinical outcomes. Study Details...
Vamsidhar Velcheti, MD, Joins NYU Langone as Director of Thoracic Medical Oncology
Clinician and researcher Vamsidhar ‘Vamsi’ Velcheti, MD, recently joined the Perlmutter Cancer Center at New York University (NYU) Langone Health as Director of Thoracic Medical Oncology. He aims to improve clinical care, increase translational and clinical research, and promote interdisciplinary ...
Monthly Vitamin D and Cancer Risk
In a study reported in JAMA Oncology, Robert Scragg, MBBS, PhD, of the School of Population Health, University of Auckland, and colleagues found that monthly high-dose vitamin D supplementation, without calcium, was not associated with a reduced risk of developing cancer. The current analysis is ...
Established, Modifiable Cancer Risk Factors
According to a new American Cancer Society report published by Gapstur et al in CA: A Cancer Journal for Clinicians, the highest priority in a national cancer control plan is the expansion of tobacco control—the intervention with the largest potential health benefits. This report is the...
ASH Honors Ross L. Levine, MD, With 2018 William Dameshek Prize
The American Society of Hematology (ASH) will present the 2018 William Dameshek Prize to Ross L. Levine, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, for his discoveries in the field of leukemia and myeloproliferative neoplasms during the 2018 ASH Annual...
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma
In an analysis of two Nordic Lymphoma Group trials with long-term follow up reported in the Journal of Clinical Oncology, Lockmer and colleagues found evidence that many patients receiving rituximab (Rituxan) as initial treatment for advanced indolent lymphoma may not require the addition of...
Fumiko Ladd Chino, MD, on Opioid-Associated Deaths in Patients With Cancer